Clinical Trial

Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients

Study acronym: LAMME
Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-18.
Status change: Not Yet Recruiting → Recruiting 2026-02-03
Trial Details
NCT Number NCT07250217
Lead Sponsor Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Collaborators: Institut de Recherche en Hématologie et Transplantation (IRHT)
Conditions Acute Myeloblastic Leukemia
Enrollment 30 participants
Start Date 2026-01-13
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-04